DSS vs NBIX · rev $19.1M vs P/E 45, rev $2.36B
DSS Inc (DSS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
DSS Inc (DSS) is a packaging & containers company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported DSS revenue for 2024-12-31 was $19.1M. Net income was -$53.7M. Revenue was down 26.4% from 2023-12-31 to 2024-12-31. DSS currently screens at market cap $8.3M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
DSS currently screens at market cap $8.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the DSS and NBIX stock pages for the full models.
Not investment advice.